The order reverses an administrative law judge’s ruling on the deal last fall. Illumina, a DNA sequencing provider, finalized its purchase of Grail in August 2021.
The FTC said the acquisition will decrease innovation in the market for early cancer detection tests and raise prices, since Illuminia is the dominant producer of the genetic sequencing technology used to analyze blood samples from the tests. The decision, which the FTC passed in a 4-0 vote, is the latest sign that the commission is ramping up challenges to anticompetitive corporate behavior.
Illumina told The Wall Street Journal it intends to appeal the FTC’s decision.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
